Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dendreon Corporation has been granted a broad European patent covering Provenge, the company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer.
Subscribe to our email newsletter
The European patent covers the composition of matter of Provenge (sipuleucel-T) as well as the company’s other active cellular immunotherapy (ACI) product candidates, such as Neuvenge (lapuleucel-T). The patent also covers methods of activating antigen presenting cells in vitro with certain fusion proteins developed by Dendreon, including the fusion protein that is used in Provenge.
Mitchell Gold, president and CEO of Dendreon, said: “The approval of this broad patent covering Provenge and our other active cellular immunotherapies in Europe is an important milestone for the company. While our priority is to obtain the approval of Provenge in the US, the issuance of this key patent solidifies the commercial potential of Provenge and our ACI platform on a more international basis.”